Scientists sorely need biomarkers of TDP-43 pathology, but finding reliable ones has been difficult. Now, two groups, working independently, have proposed a new angle—cryptic circular RNAs, or ...

Neurodegenerative proteinopathies are characterized by misfolded proteins, which are thought to spread throughout the brain by coaxing healthy proteins to join their filament ranks. Faithful ...

The field now has more evidence that tightening the tau spigot may slow Alzheimer’s progression. At this year’s Alzheimer’s Association International Conference, held July 12–15 in London, Catherine ...

Two new ApoE variants turned up in American populations. Protective variant W276C discourages ApoE from oligomerizing. Risk variant R189C promotes its lipidation. Lipidated ApoE4 disrupts microglial ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

White-matter hyperintensities, a sign of damage to the brain’s vasculature, are common on MRI scans of people with Alzheimer’s disease. Do they indicate an independent vascular co-pathology, or are ...

At last year’s AD/PD meeting in Vienna, what is now the Consortium for Biomedical Research and AI in Neurodegeneration was an idea. By this year’s AD/PD in Copenhagen, C-BRAIN had become an operating ...

Clinicians have started using blood tests of p-tau217, a marker of amyloid plaques, to help diagnose AD in routine patient care, not just research studies. Alas, at AD/PD 2026, held March 17-21 in ...

Last November, Johnson & Johnson shelved posdinemab. Top-line data from its Phase 2b trial had suggested the anti-tau antibody failed to slow deterioration in people with early-stage Alzheimer’s ...

The notion that lithium might treat Alzheimer’s was revived last year when scientists reported that the brains of people and mice with amyloid pathology are deficient in the metal ion, and that the ...

Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...

Post-marketing data chart immunotherapy performance in early-onset Alzheimer’s. The antibodies lowered amyloid and slowed functional decline. However, tangles continued to form. “These results offer ...